EphA3 CAR T cells are effective against glioblastoma in preclinical models
This study provides compelling evidence supporting the therapeutic potential of EphA3 CAR T-cell therapy against glioblastoma by targeting EphA3 associated with brain cancer stem cells and the tumor vasculature. The ability to target patient-derived glioblastoma underscores the translational significance of this EphA3 CAR T-cell therapy in the pursuit of effective and targeted glioblastoma treatment strategies.
Authors
- Rochelle C. J. D’Souza (ORCID: https://orcid.org/0000-0002-9724-4540)
- José Paulo Martins (ORCID: https://orcid.org/0000-0002-2360-403X)
- Corey Smith (ORCID: https://orcid.org/0000-0002-7550-9595)
- Lea Lekieffre
- S. Horsefield (ORCID: https://orcid.org/0000-0003-0786-3995)
- Fiona Smith (ORCID: https://orcid.org/0000-0002-8375-3870)
- M. Ranjankumar
- Rajiv Khanna (ORCID: https://orcid.org/0000-0003-2241-0353)
- Bryan W. Day (ORCID: https://orcid.org/0000-0002-8948-9089)
- Niclas Skarne
- Xiang Li (ORCID: https://orcid.org/0000-0002-9168-1598)
- Thuy T. Le (ORCID: https://orcid.org/0000-0001-9134-0104)
- Jacqueline M. Burrows
Institutions
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/jitc-2024-009403
- Citations
- 12
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- Tour de Cure